Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Del-Immune V Extra
- Development stage
- Unknown
- Lead developer
- Stellar Biotics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Del-Immune V Extra is a dietary supplement and metabiotic designed to provide immediate, broad-spectrum immune system support. It is derived from cell wall fragments of the probiotic strain Lactobacillus rhamnosus DV (NRRLB-68023) using a proprietary enzymatic process that breaks down the bacterial cell wall to release active molecules such as cell wall fragments and DNA motifs. These components act as immunomodulators, stimulating innate immune responses by activating key mediators like interferon gamma and tumor necrosis factor alpha (TNF alpha), which are involved in antiviral, antibacterial, anti-tumor, and anti-allergenic activities. Unlike live probiotics, Del-Immune V contains no live bacteria but instead uses these bioactive fragments to rapidly modulate immune function without risk of infection or antibiotic resistance transfer. The product also promotes growth of beneficial gut microbiota and supports gut health[2][4][5][6].
- Brand names
- Del-Immune V Extra
- Other names
- del-IMMUNE V ExtraDel-Immune V® Extra
02
Targets
IFNG (Interferon gamma)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on Del-Immune V Extra.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Del-Immune V Extra.